Sanofi signed a collaboration and licensing agreement with Evoq Therapeutics that could deliver more than $500 million in milestone payments tied to preclinical, development and sales goals. Evoq will provide access to its NanoDisc dendritic-cell targeting platform and Sanofi will lead clinical development and global commercialization. The deal follows Gilead’s 2023 licensing of NanoDisc for lupus and rheumatoid programs and positions Sanofi to expand its immunology pipeline. The companies disclosed the arrangement in statements; Evoq CEO David Giljohann called Sanofi a “highly credible and attractive partner” to advance NanoDisc. Sanofi framed the agreement as part of a broader push to strengthen its immunology franchise after recent asset buys, including Dren Bio’s DR-0201. NanoDisc is a subcutaneous dendritic-cell–targeting technology designed to upregulate regulatory T cells and anti-inflammatory cytokines — a platform approach that could generate multiple disease-specific candidates if preclinical work translates to human efficacy.